Clinical Trial Update: Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for NSCLC patients with EGFR mutations (Del 19 or L858R +/- T790M); study phases 1 and 2, terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-06-10